[Multiple myeloma].

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Medicina clínica (Ed. impresa)

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1201/b13347-16PMID 17594862
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• International uniform response criteria for multiple myeloma

  2007cited by this paper
• Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.

  2006cited by this paper
• Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

  2006cited by this paper
• Myeloma bone disease and treatment options.

  2006cited by this paper
• Guidelines on the diagnosis and management of multiple myeloma 2005

  2006cited by this paper
• Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.

  2006cited by this paper
• Cancer Statistics, 2006

  2006cited by this paper
• Conventional diagnostics in multiple myeloma.

  2006cited by this paper
• Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.

  2006cited by this paper
• Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials.

  2006cited by this paper
• Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.

  2006cited by this paper
• Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma.

  2006cited by this paper
• Advances in oral therapy for multiple myeloma.

  2006cited by this paper
• Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.

  2006cited by this paper
• Thalidomide and hematopoietic-cell transplantation for multiple myeloma.

  2006cited by this paper
• A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.

  2006cited by this paper
• Extended follow‐up of a phase II trial in relapsed, refractory multiple myeloma:

  2006cited by this paper
• Thalidomide in multiple myeloma

  2006cited by this paper
• Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.

  2006cited by this paper
• POEMS Syndrome.

  2005cited by this paper
• High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.

  2005cited by this paper
• Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma.

  2005cited by this paper
• Genetic Abnormalities and Patterns of Antigenic Expression in Multiple Myeloma

  2005cited by this paper
• Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

  2005cited by this paper
• Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.

  2005cited by this paper
• Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.

  2005cited by this paper
• Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.

  2005cited by this paper
• Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

  2005cited by this paper
• High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.

  2005cited by this paper
• PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

  2005cited by this paper
• Multiple myeloma: clinical features and indications for therapy.

  2005cited by this paper
• Renal, hematologic and infectious complications in multiple myeloma.

  2005cited by this paper
• Prognostic features of multiple myeloma.

  2005cited by this paper
• International staging system for multiple myeloma.

  2005cited by this paper
• An ultrasensitive method for the detection of oligoclonal IgG bands.

  2004cited by this paper
• Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma.

  2004cited by this paper
• The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.

  2004cited by this paper
• Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients

  2004cited by this paper
• Single versus double autologous stem-cell transplantation for multiple myeloma.

  2003cited by this paper
• Hyperviscosity syndrome in plasma cell dyscrasias.

  2003cited by this paper
• The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.

  2003cited by this paper
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003cited by this paper
• Serum test for assessment of patients with Bence Jones myeloma.

  2003cited by this paper
• Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

  2003cited by this paper
• Myeloma: Update on supportive care strategies

  2003cited by this paper
• High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

  2003cited by this paper
• Smoldering multiple myeloma: natural history and recognition of an evolving type

  2003cited by this paper
• Chronic but not acute graft‐versus‐host disease improves outcome in multiple myeloma patients after non‐myeloablative allogeneic transplantation

  2003cited by this paper
• Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.

  2002cited by this paper
• Solitary bone plasmacytoma and extramedullary plasmacytoma

  2002cited by this paper
• Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients

  2001cited by this paper
• Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma.

  2001cited by this paper
• Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine.

  2001cited by this paper
• Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics.

  1999cited by this paper
• Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes.

  1998cited by this paper
• A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

  1996cited by this paper

• Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation

  2025cites this paper
• Advancements in the Treatment of Multiple Myeloma

  2024cites this paper
• Multiple myeloma patients undergoing chemotherapy: Which symptom clusters impact quality of life?

  2023cites this paper
• Dose reduction and toxicity of lenalidomide-dexamethasone in multiple myeloma: A machine-learning prediction model

  2023cites this paper
• Consensus Statement: Importance of Timely Access to Multiple Myeloma Diagnosis and Treatment in Central America and the Caribbean

  2022cites this paper
• Combined Selection System to Lower the Cutoff for Plasma Cell Enrichment Applied to iFISH Analysis in Multiple Myeloma

  2018cites this paper
• Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial

  2015cites this paper
• A preliminary study of the effect of curcumin on the expression of p53 protein in a human multiple myeloma cell line

  2015cites this paper
• The impact of the type of hospital on survival of multiple myeloma patients: the MICORE study.

  2013cites this paper
• [Guidelines for the use of bisphosphonates in multiple myeloma: Recommendations of the expert committee of the Spanish Myeloma Group from the PETHEMA group].

  2010cites this paper